<DOC>
	<DOC>NCT00645294</DOC>
	<brief_summary>Open-label study of the pharmacokinetics of adefovir dipivoxil in children and adolescents infected with chronic hepatitis B.</brief_summary>
	<brief_title>Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV</brief_title>
	<detailed_description>Children and adolescents with chronic hepatitis B and compensated liver, HBeAg-positive and serum HBV DNA positive (greater than or equal to 1 x 100,000 copies/mL by Roche Amplicor Monitor PCR) received doses of adefovir dipivoxil in a cross-over design. Subjects aged 2-11 received two single doses (0.14 mg/kg and 0.3 mg/kg liquid formulation) and subjects 2-17 received one dose (10 mg liquid formulation).</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Males and females between the ages of 2 and 17 (inclusive) with chronic hepatitis B as evidenced by the following: HBsAg positive for a minimum of 6 months HBeAg positive and HBV DNA greater than or equal to 1 x 100,000 copies/mL at screening Children and adolescents with compensated liver disease ALT levels greater than or equal to 1.2 upper limit of normal (applicable to 7 to 17yearold children and adolescents only)</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Adefovir dipivoxil</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>